QC: No

Amendment Tool v1.6 06 December 2021

Short project title*:	uration of antibiotic	treatment for seps	sis							
IRAS project ID* (or REC reference if no IRAS project ID is available):	209815									
Sponsor amendment reference number*:	NSA-19									
Sponsor amendment date* (enter as DD/MM/YY):	25 May 2022									
Briefly summarise in lay language the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study. If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained (note: this field will adapt to the amount of text entered)*:	GP letter being updated to remove the adapt sepsis trial email address in order to avoid the GP from sending personal identifiable data to the incorrect team. Further information about trial can be found using the link provided in the GP letter. Clarification had also been added about not sending the clinical trial management group any personal identifiable data.									
				Specific stu	dy					
Project type (select):				Research tis	sue bank					
				Research da	itabase					
Has the study been reviewed by a UKECA-recognised Res	search Ethics	Y	es	No						
Committee (REC) prior to this amendment?:										
What type of UKECA-recognised Research Ethics Commit is applicable? (select):	ttee (REC) review	NHS/HSC REC Ministry of Defence (MoDREC								
Is all or part of this amendment being resubmitted to the R Committee (REC) as a modified amendment (i.e. a subst amendment previously given an unfavourable opinion)?		Y	es	No						
Where is the NHS/HSC Research Ethics Committee (REC	that reviewed	England	Wales	Scotland	Northern Irelan					
the study based?:	,	Yes	No	No	No					
Was the study a clinical trial of an investigational medicinal OR does the amendment make it one?:	product (CTIMP)	Y	es	No						
Was the study a clinical investigation or other study of a midoes the amendment make it one?:	edical device OR	Y	es	No						
Did the study involve the administration of radioactive subsrequiring ARSAC review, OR does the amendment introdu		Y	es	ı	No					
Did the study involve the use of research exposures to ioni (not involving the administration of radioactive substances) amendment introduce this?:	Y	es	No							
Did the study involve adults lacking capacity OR does the a introduce this?:	Y	es	No							
Did the study involve access to confidential patient informa direct care team without consent OR does the amendment		Y	es	No						
Did the study involve prisoners or young offenders who are supervised by the probation service OR does the amendmenthis?:		Y	es	No						
Did the study involve children OR does the amendment int	roduce this?:	Υ	es	ı	No					
Did the study involve NHS/HSC organisations prior to this	amendment?:	Y	es	1	No					
Did the study involve non-NHS/HSC organisations OR doe amendment introduce them?:					No					
*		England	Wales	Scotland	Northern Irelar					
Lead nation for the study:		Yes	No	No	No					
Which nations had participating NHS/HSC organisations p amendment?		Yes	Yes	Yes Yes						
Which nations will have participating NHS/HSC organisation	ons after this	Yes Yes Yes Ye								

Section 2: Summary of change(s)

Please note: Each change being made as part of the amendment must be entered separately. For example, if an amendment to a clinical trial of an investigational medicinal product (CTIMP) involves an update to the Investigator's Brochure (IB), affecting the Reference Safety Information (RSI) and so the information documents to be given to participants, these should be entered into the Amendment Tool as three separate changes. A list of all possible changes is available on the "Glossary of Amendment Options" tab. To add another change, click the "Add another change" box.

Change 1

Area of change (select)*:	Study Documents								
Specific change (select - only available when area of change is selected first)*:	Other minor change to study documents (e.g. information sheets, consent forms, questionnaires, letters) that can be implemented within existing resource in place at participating organisations - Please specify in the free text below								
Further information In particular, please describe why this change can be implemented within the existing resource in place at the participating organisations (free text - note that this field will adapt to the amount of text entered)*	The GP letter has been updated to remove the Adapt Sepsis trial email address in order to avoid breaches of personal identifiable information being sent to the incorrect team, this should have no impact on the resource in place at the participating organisation.								
Applicability:		England	Wales	Scotland	Northern Ireland				
Where are the participating NHS/HSC organisations located by this change?*:	d that will be affected	Yes	Yes	Yes	Yes				
	articipating NHS/HSC organisations be affected by this change, or only please note that this answer may affect the categorisation for the				Some				
				Add another change					

Section 3: Declaration(s) and lock for submission

Declaration by the Sponsor or authorised delegate

- I confirm that the Sponsor takes responsibility for the completed amendment tool
 I confirm that I have been formally authorised by the Sponsor to complete the amendment tool on their behalf

Name [first name and surname]*:	Mohammed Zubair
Email address*:	Mohammed.Zubair@manchester.ac.uk

Lock for submission

Please note: This button will only become available when all mandatory (*) fields have been completed. When the button is available, clicking it will generate a locked PDF copy of the completed amendment tool which must be included in the amendment submission. Please ensure that the amendment tool is completed correctly before locking it for submission.

Lock for submission

After locking the tool, proceed to submit the amendment online. The "Submission Guidance" tab provides further information about the next steps for the amendment.

Section 4: Review bodies for the amendment

Please note: This section is for information only. Details in this section will complete automatically based on the options selected in Sections 1 and 2.

								F	Review	bodie	s								
	UK wide:				Eng	England and Wales:			Scotland:			Northern Ireland:							
	REC	Competent Authority MHRA - Medicines	Competent Authority MHRA - Devices	ARSAC	Radiation Assurance	UKSW Governance	REC (MCA)	CAG	HMPPS	HRA and HCRW Approval	REC (AWIA)	РВРР	SPS (RAEC)	National coordinating function	HSC REC	HSC Data Guardians	Prisons	National coordinating function	Category:
Change 1:						(Y)				(Y)				(Y)				(Y)	С
Overall reviews for the amendme	nt:																		
Full review:						N				N				N				N	
Notification only:						Υ				Υ				Υ				Υ	
Overall amendment type:	Non-substantial, no study-wide review required																		
Overall Category:	С		•		•				•			•					•		